基于网络铁死亡相关的长非编码RNA预测肝细胞癌患者预后研究*

doi:10.3969/j.issn.1672-5069.2022.04.026

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (4): 558-562.doi: 10.3969/j.issn.1672-5069.2022.04.026

基于网络铁死亡相关的长非编码RNA预测肝细胞癌患者预后研究^*

布凡, 柴剑波, 白冰, 王万宇, 赵永厚

150036 哈尔滨市黑龙江中医药大学(布凡,王万宇);黑龙江神志医院(赵永厚,柴剑波,白冰)

收稿日期:2021-12-17 出版日期:2022-07-10 发布日期:2022-07-14
通讯作者: 赵永厚,E-mail: zyszbx2020@126.com
作者简介:布凡,男,25岁,硕士研究生。E-mail:547782560@qq.com
基金资助:
^*国家自然科学基金资助项目(编号:81572939)

Cyber-based study on ferroptosis-related long non-coding RNA signature predicting prognosis of patients with hepatocellular carcinoma

Bu Fan, Chai Jianbo, Bai Bing, et al

Heilongjiang University of Chinese Medicine,Harbin 150036,Heilongjiang Province, China

Received:2021-12-17 Online:2022-07-10 Published:2022-07-14

摘要/Abstract

摘要： 目的探讨构建基于铁死亡相关长链非编码RNA(lncRNA)的预后风险模型预测肝细胞癌(HCC)患者预后的价值。方法自癌症基因组图谱TCGA数据库下载HCC患者RNA测序数据。基于HCC差异水平的铁死亡相关lncRNAs构建预后风险模型。结果鉴定了5个基于HCC差异水平的铁死亡相关lncRNAs;Kaplan-Meier分析显示,高风险lncRNAs与HCC预后不良相关,预测3 a生存率的ROC曲线下面积(AUC)为0.873;单样本基因集富集分析(ssGSEA)发现低风险组与高风险组细胞溶解活性、MHCI类分子、I型INF反应、II型INF反应存在显著性差异(P<0.05);免疫检查点显示,两组CD44、TNFRSF4和CD276等水平也存在显著性差异(P<0.05)。结论通过生物信息学方法筛选出5个基于HCC差异水平的铁死亡相关lncRNAs构建的预后风险模型为HCC防治研究奠定了一定的基础。

关键词: 肝细胞癌, 铁死亡, 长链非编码RNA, TCGA数据库

Abstract: Objective The purpose of this study was to investigate the prognosis of patients with hepatocellular carcinoma (HCC) by a prognostic risk model we constructed based on the cyber-arisen materials on ferroptosis-related long non-coding RNAs (lncRNAs). Methods The RNA sequencing data from patients with HCC were downloaded from the Cancer Genome Atlas TCGA database. A prognostic risk model was constructed based on differentially expressed iron death-associated lncRNAs in HCC tissues. Results Five differentially expressed lncRNAs associated with HCC prognosis were identified, and the Kaplan-Meier analysis showed that the high-risk lncRNAs were associated with poor prognosis in patients with HCC, with an area under the ROC curve (AUC) of 0.873 for 3-year survival;the single sample gene set enrichment analysis (ssGSEA) revealed immuno- and tumor-related pathways in low-risk populations; the differential analysis of immune functions showed that there were significant differences in cytolytic activity, type I INF response and type II INF response between patients with low and high risk; the immune checkpoint showed that there were also significant differences in the expression of CD44, TNFRSF4 and CD276 between the two groups. Conclusion Five ferroptosis-related lncRNAs impacting the prognosis of patients with HCC are selected by bioinformatics, and we thereby construct a prognostic risk model, which might lay the foundation for the further prevention and therapeutic study on HCC.

Key words: Hepatocellular carcinoma, Ferroptosis, Long non-coding RNA, TCGA database

布凡, 柴剑波, 白冰, 王万宇, 赵永厚. 基于网络铁死亡相关的长非编码RNA预测肝细胞癌患者预后研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 558-562.

Bu Fan, Chai Jianbo, Bai Bing, et al. Cyber-based study on ferroptosis-related long non-coding RNA signature predicting prognosis of patients with hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2022, 25(4): 558-562.

参考文献

[1] Bray F,Ferlay J,Soerjomataram I,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin,2018,68(6),394-424.
[2] Shanker M,Liu H,Lee Y,et al. Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium.J Gastroenterol Hepatol,2021,36(4),873-884.
[3] Vagefi P,Dodge J,Yao F,et al. Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation.Liver Transplant,2015,21(2),187-194.
[4] 周新民,丁小鹏. 基础肝病治疗在原发性肝癌综合治疗中的重要作用.实用肝脏病杂志,2021,24(1),4-6.
[5] Wang Y,Wei Z,Pan K,et al. The function and mechanism of ferroptosis in cancer.Apoptosis, 2020,25(11-12),786-798.
[6] Yao J,Chen X,Liu X,et al. Characterization of a ferroptosis and iron-metabolism related lncRNA signature in lung adenocarcinoma.Cancer Cell Int,2021,21(1),340.
[7] Newman A M,Liu C L,Green M R,et al. Robust enumeration of cell subsets from tissue expression profiles.Nat Met, 2015,12(5),453-457.
[8] Charoentong P,Finotello F,Angelova M,et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade.Cell Rep,2017,18(1),248-262.
[9] Yi M,Nissley D V,McCormick F,et al. ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications.Sci Rep,2020,10(1),10258.
[10] Li T,Fan J,Wang B,et al. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells.Cancer Res,2017,77(21),e108-e110.
[11] Vickers A J,Elkin E B. Decision curve analysis: a novel method for evaluating prediction models.Med Dec Mak,2006,26(6),565-574.
[12] Zhao S,Lin C,Yang T,et al. Expression of long non-coding RNA LUCAT1 in patients with chronic obstructive pulmonary disease and its potential functions in regulating cigarette smoke extract-induced 16HBE cell proliferation and apoptosis.J Clin Lab Anal,2021,35(7),e23823.
[13] Wang X,Ou H,Zhou L,et al. Long non-coding RNA LUCAT1 promotes the progression of clear cell renal cell carcinoma via the microRNA-375/YAP1 axis.Exp Therap Med,2021,22(1),754.
[14] Ma M,Li L,Long F,et al. MiR-133b inhibits colorectal cancer metastasis via lncRNA-LUCAT1.Future oncology (London, England),2021,17(9),1013-1023.
[15] Jiao Y,Li Y,Ji B,et al. Clinical value of lncRNA LUCAT1 expression in liver cancer and its potential pathways.J Gastrointest Liver Dis,2019,28(4):439-447.
[16] Lou Y,Yu Y,Xu X,et al. Long non-coding RNA LUCAT1 promotes tumourigenesis by inhibiting ANXA2 phosphorylation in hepatocellular carcinoma.J Cell Mol Med, 2019,23(3),1873-1884.
[17] Chen Y,Peng C,Chen J,et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.Mol Cancer,2019,18(1),127.

基于网络铁死亡相关的长非编码RNA预测肝细胞癌患者预后研究^*

Cyber-based study on ferroptosis-related long non-coding RNA signature predicting prognosis of patients with hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王晶, 张洁, 赵静. 超声造影联合声触诊组织量化技术鉴别肝血管瘤与肝细胞癌价值研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 575-578.
[2]	金盼盼, 张岭漪. PIVKA-II:一种新型乙型肝炎相关肝癌诊断标记物研究进展[J]. 实用肝脏病杂志, 2022, 25(4): 605-608.
[3]	薛旗, 徐琊芸, 李婕. 肝脏疾病细胞铁死亡研究进展^*[J]. 实用肝脏病杂志, 2022, 25(3): 449-452.
[4]	杨蕊旭, 范建高. 非酒精性脂肪性肝病相关肝细胞癌流行病学与筛查^*[J]. 实用肝脏病杂志, 2022, 25(2): 153-156.
[5]	王欣然, 蒋燕东, 张猛. 超声引导下放射性粒子植入治疗肝细胞癌患者短期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 263-266.
[6]	余涛, 付路路, 陈方, 田园. 超声造影灌注时相分析在肝硬化背景下对肝脏增生结节的诊断价值[J]. 实用肝脏病杂志, 2022, 25(2): 267-270.
[7]	王连双, 张瑶, 单涛, 张记, 吕志斌, 薛明. 19例原发性肝癌心脏转移患者超声特征表现和预后分析^*[J]. 实用肝脏病杂志, 2022, 25(2): 271-274.
[8]	李欢, 李扬, 杜娟, 梅放, 王玉湘, 郭丽梅. 肝细胞癌组织Glypican3和Sonic Hedgehog蛋白表达及其功能分析^*[J]. 实用肝脏病杂志, 2022, 25(1): 83-87.
[9]	肖倩, 周展, 胡小丽. 肝细胞癌患者肝内病灶超声造影参数变化^*[J]. 实用肝脏病杂志, 2022, 25(1): 92-95.
[10]	中国肝炎防治基金会肝细胞癌筛查和监测项目专家组. 慢性乙型肝炎病毒感染者肝细胞癌筛查和监测[J]. 实用肝脏病杂志, 2021, 24(6): 776-785.
[11]	贾坤, 苏建荣, 孙伟. 慢性丙型肝炎患者血清和外泌体LncRNA HEIH水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(6): 823-826.
[12]	吴慧娟, 何年安, 谢蠡, 叶显俊, 章生龙, 刘力. 超声造影联合血清CA19-9鉴别诊断胆管细胞癌与肝细胞癌应用研究[J]. 实用肝脏病杂志, 2021, 24(6): 903-906.
[13]	周正, 刘玮. 肝血管瘤、肝细胞癌和肝血管平滑肌脂肪瘤超声造影特点观察^*[J]. 实用肝脏病杂志, 2021, 24(6): 911-914.
[14]	赵鹏飞, 祖红梅, 辛晓恩, 彭军宁, 严兆兰, 马存凯, 李雅静, 杨硕. 肝细胞癌发病危险因素Logistic回归分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 927-929.
[15]	梁旭, 刘圆圆, 杨学刚, 任静. 基于2018年版肝脏影像报告数据系统对比分析CT和MRI诊断肝细胞癌的效能^*[J]. 实用肝脏病杂志, 2021, 24(5): 725-728.